Rhythm Pharmaceuticals, Inc. (RYTM) SEC Filings & Earnings Calls

Ex-U.S. revenue decline due to French charge

“Ex-U.S. revenue decreased 13% sequentially due to a $3.8 million retrospective charge in France.”

Dependence on HO launch success

“Strong initial demand but early stage; sustainability of growth depends on continued adoption and reimbursement.”

Pipeline concentration risk

“RM-718 data based on small sample (n=7); further validation needed.”

Customer concentration

“approximately 72 % and 66 % of all the Company’s revenue was generated from a single customer in the United States.” · word for word

Operating losses continue

“The Company has incurred operating losses and experienced negative cash flows from operations since inception.” · word for word

Dependence on third-party manufacturers

“The Company relies on third-party manufacturers and suppliers for the manufacture and supply of its product.” · word for word

Customer concentration risk

“approximately 61 % and 65 % of all the Company’s revenue was generated from a single customer in the United States.” · word for word

Operating loss trajectory

“Loss from operations ( 52,361 ) ( 47,004 )” · word for word

Clinical trial failure risk: Phase 3 EMANATE trial did not meet primary endpoint.

“Phase 3 EMANATE trial did not achieve primary endpoint in each of its four independent substudies.”

Regulatory dependency: Japan PMDA decision pending; EU launch timing uncertain.

“Japan PMDA decision anticipated H2 2026; EU launches anticipated 2027.”

Competition risk in rare disease space.

“No direct competitor mentioned but rare disease market may have emerging therapies.”

Say-on-Pay vote decline

“At our 2025 annual meeting, 69.4% of our stockholders who were present or represented by proxy at the annual meeting and entitled to vote on the proposal voted to support a non-binding, advisory proposal related to the compensation of our named executive officers, a significant decrease from the 97% approval the year before.” · word for word

Classified board structure may face stockholder opposition

“Some stockholders expressed concern regarding our corporate governance structure, in particular sunsetting our classified board structure.” · word for word

Dependence on key personnel and retention risk

“We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees.” · word for word

Regulatory approval risk: CHMP opinion positive but EC decision pending; final approval not guaranteed.

“The CHMP opinion will now be reviewed by the European Commission (EC), which has the authority to grant and expand marketing authorizations for medicinal products in the European Union.” · word for word

Commercialization risk: successful launch and market penetration in EU uncertain; competition and pricing pressures.

“risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide” · word for word

Commercial execution risk for new indication; reimbursement and market access challenges.

“Rhythm is committed to supporting access for patients to its medicines; Rhythm InTune provides personalized, ongoing educational support... assistance with insurance navigation” · word for word

Competition from potential future therapies for acquired HO.

“First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity” · word for word

Primary endpoint failure in Phase 3 trial for setmelanotide; pipeline risk for next-generation MC4R agonists

“The four substudies of this global, Phase 3 trial evaluating setmelanotide did not meet primary endpoints.” · word for word

Regulatory approval risk remains; PDUFA date March 20, 2026

“sNDA under review by FDA with PDUFA goal date of March 20, 2026”

Dependence on IMCIVREE for revenue; pipeline milestones subject to regulatory and clinical risk.

“Revenue concentrated in IMCIVREE; PDUFA date March 20, 2026 for acquired HO; Phase 3 EMANATE data expected March 2026.”

Continued operating losses and need for additional capital

“We have incurred significant operating losses since our inception, anticipate that we will incur continued losses for the foreseeable future and may never achieve profitability.” · word for word

Dependence on regulatory approvals for label expansion

“Pending regulatory approvals, we anticipate launching IMCIVREE for acquired hypothalamic obesity in the United States in 2026, based on our FDA-assigned Prescription Drug User Fee Act (PDUFA) goal date of March 20, 2026.” · word for word

Small addressable patient populations

“The number of patients with each of the MC4R pathway variants we are targeting is small and has not been established with precision.” · word for word

Revenue interest financing obligations

“Our Revenue Interest Financing Agreement with Healthcare Royalty Partners could restrict our ability to commercialize IMCIVREE, limit cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations.” · word for word

Preliminary results subject to audit adjustment

“These estimates are based on the information available to the Company at this time. The Company's financial closing and audit procedures for the fourth quarter and full year 2025 are not yet complete.” · word for word

Regulatory delay for key product approval

“FDA has extended by three months the review period for the supplemental New Drug Application” · word for word

International revenue decline due to French pricing adjustment and ordering variability.

“Revenue of $13.1 million, or 26% of product revenue, was generated outside the United States, a sequential decrease of $3.4 million or 21%. In October 2025, Rhythm agreed to a final reimbursed price for IMCIVREE for BBS and POMC and LEPR deficiencies with the French Economic Committee for Health Products (CEPS). Since 2022, IMCIVREE has been available to pat” · word for word

Regulatory dependency for hypothalamic obesity approval; PDUFA Dec 20, 2025.

“FDA accepted for filing the Company’s sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity. The FDA granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2025.” · word for word

Customer concentration

“For the three months ended September 30, 2025, approximately 74% of all the Company's revenue was generated from a single customer in the United States.” · word for word

Accumulated deficit and operating losses

“As of September 30, 2025, the Company had an accumulated deficit of $1.3 billion.” · word for word

Dependence on third-party manufacturers

“The Company relies on third-party manufacturers and suppliers for the manufacture and supply of its product.” · word for word

Dependence on genetic testing vendors

“The Company relies on separate third parties to perform genetic testing in the United States and Europe, respectively.” · word for word